ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.38
0.00 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.38
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume187,572
Market Cap61.008M
Beta (3Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.05
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company submitted a 510(k) notification to the U.S. Food and Drug Administration (FDA or “the Agency”) for its AC5ä Topical Gel (AC5)1 and has received acknowledgement from the Agency that the submission has been received. The purpose of the 510(k) notification is to allow for commercial use of AC5 on external wounds for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. Terrence W. Norchi, MD, President and CEO of Arch, said, “We are happy to have initiated and completed the necessary steps required to file this submission during the third calendar quarter.

  • GlobeNewswire21 days ago

    Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

    FRAMINGHAM, Mass., Sept. 25, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the Ladenburg Thalmann ...

  • GlobeNewswirelast month

    Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical Gel (AC5)1. The study was designed to address a request by the Food and Drug Administration (FDA or “the Agency”). The objective of this Study (“Cumulative Irritancy Assay with Delayed Challenge for Allergic Contact Dermatitis Potential of AC5™ Topical Gel (AC5) in Healthy Volunteers”) was to assess irritation and sensitization potential (development of allergic contact dermatitis) of AC5 after repeat applications and then a delayed challenge application of the product to the skin.

  • GlobeNewswire2 months ago

    Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018

    FRAMINGHAM, Mass., Aug. 28, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20 ...

  • GlobeNewswire2 months ago

    Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018

    FRAMINGHAM, Mass., Aug. 16, 2018-- Arch Therapeutics, Inc., developer of AC5™ Topical Gel, today announced that new research involving AC5™ will be presented in a poster at the 2018 Military Health System ...

  • GlobeNewswire3 months ago

    Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former President & CEO of OncoSec Medical, Inc. (ONCS), to its Board of Directors (the “Board”) as an independent member effective as of July 19, 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch’s Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Mr. Dhillon is experienced and skilled in capital markets and in establishing strategic partnerships, including early and late stage deals with Merck and Pfizer.

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire7 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...